Concentrating Research Resources on rogocekib
First written in FY2025-H1. 3 of 5 entries say "Restated". Latest entry: 2026-10-15.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「In light of these circumstances, we are concentrating internal resources on rogocekib, our most promising pipeline, to accelerate its development. For our other pipelines, we are considering flexible strategies, including early partnering, and are working to optimize the allocation of management resources.」
The company reaffirmed its policy of concentrating internal resources on rogocekib and adopting flexible strategies for its other pipeline programs, including early partnering. - FY2025AdvancedAnnual report
「We believe that focusing even more closely on rogocekib, our most advanced development program, accelerating its development and obtaining regulatory approval will contribute to enhancing corporate value. Accordingly, we are concentrating our internal resources on rogocekib and are proactively considering a broad range of possibilities for CTX-439 and the GCN2 inhibitor, including early partnering.」
The concentration of internal resources on rogocekib has continued and become more concrete as a clear capital allocation policy, while early partnering for CTX-439 and the GCN2 inhibitor is being considered in parallel. - FY2025-H1First statedAnnual report
「In light of the current focus of our research resources on rogocekib, in addition to advancing our own research and development」
The company stated for the first time that its concentration of research resources on rogocekib among its 5 pipelines was behind its consideration of early partnering for CTX-439 and GCN2.